Haptoglobin for Treating Secondary Neurological Outcome Post-Hemorrhagic Stroke
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Summary
The European Patent Office published patent application EP3968988A1 for haptoglobin as a therapeutic agent for treating adverse secondary neurological outcomes following hemorrhagic stroke. Co-applicants Universität Zürich and CSL Behring AG seek patent protection across 35 designated EPC contracting states including all EU member states. The A1 publication indicates the application passed formal examination and is now publicly accessible for opposition purposes.
What changed
EPO published patent application EP3968988A1 claiming haptoglobin for use in treating adverse secondary neurological outcomes following hemorrhagic stroke. The application names inventors HUGELSHOFER, Michael, SCHAER, Christian, and SCHAER, Dominik from co-applicants Universität Zürich and CSL Behring AG. The patent application covers IPC classifications including A61K 38/16 (proteins), A61K 38/42 (hemoglobin), and A61P 9/10 (cerebrovascular diseases).
Pharmaceutical and biotechnology companies developing stroke therapies should review the patent claims to assess freedom-to-operate implications. Research institutions conducting related neurological research may wish to evaluate potential licensing opportunities. The patent grants exclusive rights for the designated territories; no compliance actions or deadlines are associated with this publication notice.
Source document (simplified)
HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE
Publication EP3968988A1 Kind: A1 Mar 25, 2026
Applicants
Universität Zürich, CSL Behring AG
Inventors
HUGELSHOFER, Michael, SCHAER, Christian, SCHAER, Dominik
IPC Classifications
A61K 31/4245 20060101AFI20201127BHEP A61K 33/26 20060101ALI20201127BHEP A61K 38/16 20060101ALI20201127BHEP A61K 38/42 20060101ALI20201127BHEP A61P 9/10 20060101ALI20201127BHEP A61P 43/00 20060101ALI20201127BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.